News

Deal Announcements

Clarus Therapeutics Nets Venture Capital Debt

Monday, June 16, 2014 5:30:00 AM PDT | VentureDeal
   Northbrook, Illinois  --  Biotechnology company Clarus Therapeutics has secured $31.5 million in venture capital debt investment.

Clarus is developing an oral testosterone product for men with testosterone deficiency.

C-Bridge Capital led the round, which also included BioVeda Capital and Pavilion Capital Partners.

The company said it would use the funding to support its new drug application approval process.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1